IMMUNOGEN INC

Form 3 May 19, 2016

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement IMMUNOGEN INC [IMGN] A Enyedy Mark J (Month/Day/Year) 05/16/2016 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 24 CONCORD SQUARE (Check all applicable) (Street) 6. Individual or Joint/Group Filing(Check Applicable Line) 10% Owner _X_ Director _X_ Form filed by One Reporting _X__ Officer Other Person (give title below) (specify below) BOSTON, MAÂ 02118 Form filed by More than One Chief Executive Officer Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities 4. Nature of Indirect Beneficial 1. Title of Security Beneficially Owned Ownership (Instr. 4) Ownership (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) D Â Common Stock $75,100^{(1)}$

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 $Table\ II\ -\ Derivative\ Securities\ Beneficially\ Owned\ (\textit{e.g.},\ puts,\ calls,\ warrants,\ options,\ convertible\ securities)$

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security		4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership
			(Instr. 4)		Price of	Derivative	(Instr. 5)
	D (F . 11 F	Expiration Date	Title	Amount or Number of	Derivative	Security:	
	Date Exercisable E				Security	Direct (D)	
	D					or Indirect	

Edgar Filing: IMMUNOGEN INC - Form 3

Stock Option (right to 05/16/2017(2) 05/16/2026 Common 300,000 \$ 5.65 D Â

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Enyedy Mark J 24 CONCORD SQUARE BOSTON, MAÂ 02118

X Â Â Chief Executive Officer Â

Signatures

buy)

/s/ Craig Barrows, attorney in fact 05/19/2016

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations, See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 75,000 of these shares are restricted stock which vest annually in four equal installments commencing on May 16, 2017.
- (2) Exercisable as to 75,000 shares commencing on May 16, 2017, 75,000 shares commencing on May 16, 2018, 75,000 shares commencing on May 16, 2019 and 75,000 shares commencing on May 16, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2